enGene Holdings Inc (Nasdaq: ENGN), a Canada-based clinical-stage genetic medicines company, announced on Tuesday that it has named Raj Pruthi MD MHA FACS as its new senior vice president, Urologic Oncology and Clinical Development.

Dr Pruthi is to report to enGene's chief medical officer, Dr Richard Bryce.

In the new role, Pruthi will be responsible for supporting the clinical development of enGene's non-viral, intravesical lead product candidate, EG-70, across the urologic space, including through engagement with the urological community. EG-70 is subject to a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC),

Dr Pruthi has most recently served as global medical affairs leader, Bladder Cancer and senior medical director, Oncology (Global – Prostate and Bladder Cancer) at Johnson & Johnson Innovative Medicine. He serves as the chair of the Advisory Council for Urology of the American College of Surgeons and serves on its Board of Governors. Presently, he is an adjunct professor in the Department of Urology at the Donald and Barbara Zucker School of Medicine at Hofstra University/Northwell and earlier served as professor and chair of both the UCSF Department of Urology and the Department of Urology at the University of North Carolina, Chapel Hill. He has served as a member of the American Board of Urology (ABU)/ American Urological Association (AUA) Examination Committee and is past-president for the Society of Academic Urology. He has worked on the Guidelines Committee and helped to develop the AUA Guidelines on the Management of Non-muscle Invasive Bladder Cancer. He has also worked on the Bladder Cancer Guidelines Committee of the International Consultation on Urological Diseases.